Agree with him or not, he does make a valid point. It will...

First 4037 Last

Share
Profile

Follow
yanlin

6,306 Posts.

1793

27/10/17

15:48

Post #: 28260882
Share
Originally posted by FlashFish ↑

Taken with a grain of salt

Why the lithium miners have sunk lower today

https://www.********.au/2017/10/26/why-the-lithium-miners-have-sunk-lower-today/

Although the market as a whole has tumbled lower today, one group of shares has fallen more than most.
In afternoon trade almost all of Australia’s lithium miners have sunk deep into the red following a broad sell-off of the industry.
Here’s the state of play at the time of writing:

The Galaxy Resources Limited (ASX: GXY) share price is down 6% to $3.46.

The Kidman Resources Ltd (ASX: KDR) share price has fallen 4% to $1.25.

The Lithium Australia NL (ASX: LIT) share price is down 1.5% to 17.7 cents.

The Mineral Resources Limited (ASX: MIN) share price is off 2% to $18.40.

The Orocobre Limited (ASX: ORE) share price is down 1.5% to $4.48.

The Pilbara Minerals Ltd (ASX: PLS) share price has tumbled 4% to 77 cents.

Why have they sunk lower?
With no notable news out of the industry or falls in the lithium price, I feel today’s declines are likely to be a case of profit taking following strong rallies over the last few weeks.
After all, prior to today, Galaxy, Kidman, and Pilbara Minerals shareholders had seen their respective shares rise by at least 90% over the last three months.
Whilst I am very bullish on their long-term prospects, even as a Galaxy shareholder I felt uneasy by this strong gain in such a short space of time. Hence why I stopped recommending Galaxy as a buy.
And while Galaxy is looking a lot more attractive at this level, I would suggest investors hold off an investment until the dust settles.

Expand

Agree with him or not, he does make a valid point.
It will bounce back on news.
GXY Price at posting: $3.45 Sentiment: None Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

There are more pages in this discussion • 19,430 more messages in this thread...

First 4037 Last

Add GXY (ASX) to my watchlist

Agree with him or not, he does make a valid point. It will...

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News